ArticleTrials2026
Tracking outcome changes in benign prostatic hyperplasia trials: a version history review of ClinicalTrials.gov records.
Article in Trials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBenign prostatic hyperplasia (BPH) is a common condition with trials that frequently rely on subjective outcomes. While federal regulations require prospective outcome registration in ClinicalTrials.gov, modifications to these outcomes are permitted and often unjustified, potentially compromising transparency and interpretability. This study examined the frequency, timing, type, and transparency of prespecified outcome modifications in BPH trials.
methodsWe conducted a registry-based cross-sectional analysis of interventional BPH trials registered on ClinicalTrials.gov between January 18, 2017, and December 31, 2024. Eligible trials enrolled adult males, reported posted results, contained prespecified outcomes in both original and most recent registry versions, and were linked to peer-reviewed publications. Modifications were categorized by type (e.g., additions, removals, rewordings), timing, and severity. Key variables included the Outcome Load Index (OLI) and a Severity-Weighted Change Score. Statistical analyses included Cochran's Q tests, Kaplan-Meier time-to-event analysis, and correlation tests.
resultsOf 1383 records screened, 36 trials met inclusion criteria. All trials (100%) exhibited at least one outcome modification, none of which were justified. Modifications occurred exclusively after primary completion; half occurred before publication and half after. Minor rewording and broad-to-specific definitional shifts were most common. Changes were significantly more frequent in secondary outcomes (p < 0.01). Severity scores varied widely but were not consistently associated with funder or intervention type. OLI showed weak correlation with modification frequency (r = 0.17).
conclusionsIn this registry-based analysis of BPH clinical trials, outcome modifications were universal, occurred exclusively after primary completion, and were never justified in either the registry or corresponding publications. These findings highlight a persistent gap in transparency that could affect the interpretability of trial results. Greater oversight of registry version histories and stronger disclosure standards are needed to ensure the credibility of outcome reporting in BPH research and beyond.
trial registrationRegistered on the Open Science Framework. The study was additionally submitted to PROSPERO; the OSF registration is the protocol of record. Registered on July 17, 2025.
Indexed as
Identifiers
42458564What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.